Ensitrelvir

• CAT Number: I045200
• CAS Number: 2647530-73-0
• Molecular Formula: C22H17ClF3N9O2
• Molecular Weight: 531.88
• Purity: ≥95%
• Synonyms: 6-[(6-chloro-2-methylindazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4-dione
• InChI: InChI=1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)
• InChIKey: QMPBBNUOBOFBFS-UHFFFAOYSA-N
• SMILES: CN1C=C2C=C(C(=CC2=N1)Cl)NC3=NC(=O)N(C(=O)N3CC4=CC(=C(C=C4F)F)F)CC5=NN(C=N5)C

Ensitrelvir（Cat No.:I045200）is an orally bioavailable, potent inhibitor of the SARS-CoV-2 main protease (Mpro, 3CLpro), a critical enzyme for viral polyprotein cleavage and replication. By targeting Mpro, Ensitrelvir disrupts viral maturation, effectively halting replication. It has demonstrated strong antiviral activity against various SARS-CoV-2 variants, including Omicron, in preclinical and clinical studies. Designed for convenient oral dosing, it offers potential for early outpatient COVID-19 treatment. Ensitrelvir is a valuable research tool for studying coronavirus protease biology and represents a promising therapeutic candidate for pandemic preparedness and viral infection control.